Genmab A/S (NASDAQ:GMAB) Receives $45.20 Average Target Price from Analysts
Shares of Genmab A/S (NASDAQ:GMAB – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price […]
Shares of Genmab A/S (NASDAQ:GMAB – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price […]
